Thanks, Josh, and thank you, everyone, for joining us this afternoon. Overall, I was pleased with our fourth quarter and full year 2023 results, and particularly in how we have responded to the challenging market conditions in our Nurse and Allied segments as health systems seek ways to reduce their reliance on contingent labor. After declining in the first half of 2023, travel demand remained fairly stable. However, coming into the new year, we were seeing another pullback in orders, which appears to be industry-wide across most specialties and geographies. Many systems are nonetheless seeing increases in volumes, which we believe will ultimately translate into rising demand for our services. And with our focus on innovation and operational excellence, as well as the health of our balance sheet, Cross Country is well positioned to weather these near-term headwinds, and we believe we are poised to see sequential growth in the back half of the coming year. Now I’d like to take a moment to reflect on our full year performance. We generated $144 million of adjusted EBITDA, our second best year in company history, following the record year in 2022. We also had a record year for cash flow from operations, generating $249 million, which enabled us to end the year with a strong debt-free balance sheet. In addition, we invested more than $20 million on technology initiatives and repurchased 2.3 million shares of stock, representing approximately 6% of our outstanding shares this year. Perhaps the most noteworthy accomplishment from 2023 was the rollout of our vendor management system Intellify. This VMS technology amplifies and enhances productivity by more effectively managing, deploying, and anticipating workforce needs for our clients. Throughout the year, we witnessed the level of interest in this technology grow, leading to a series of wins that exceeded internal targets. In fact, two fairly sizable deals that we closed early in the fourth quarter were fully implemented before year-end, demonstrating the speed at which we can deploy this technology. In addition to our client-facing Intellify offering, we rebranded our Xperience app last year, which is a candidate-facing tool that enables clinicians with the power to manage their careers anytime, anyplace they want. Equally exciting, Xperience is on our roadmap to be fully integrated into Intellify. Unlike conventional job matching, Xperience ensures a precise alignment of clinicians with roles that uniquely match their skills and aspirations. In 2023, we had more than 18,000 app downloads and over 100,000 unique viewers that accessed Xperience through our mobile app and website. And finally, we launched data aggregation services, or DAS, which offers unique insights on bill rate trends that help hospitals validate their costs by providing real-time benchmarking and visibility. From an MSP and vendor-neutral sales perspective, 2023 was a very active year in our industry. And though we experienced a higher level of attrition in the earlier part of the year, we left 2023 on a very positive trajectory from both a retention and new client perspective, as well as having a robust pipeline. The annualized spend under management from our recent wins is estimated to be over $125 million when fully ramped. And since late December, we’ve had two more wins, including one verbal, with total estimated annual spend of more than $75 million. We believe that these and other wins we expect to close throughout the year will provide some tailwinds in the second half of the coming year. It’s also interesting to note that we’ve seen more balanced interest from hospital systems between MSP and vendor neutral programs, and we are strategically positioned to capitalize and grow share on both these fronts. Our focus for 2024 is on continuing to expand our client base and growing our relationships with existing clients through an expansion of services. And though we are always focused on driving efficiency, our plans for the coming year include leveraging both our offshore operations, as well as continuing to invest in cutting-edge technologies, such as AI agents and robotic process automation. These efforts will allow us to lower costs, enhance predictive job matching, improve talent sourcing, and assess candidate suitability. I look forward to sharing our progress on these and many other initiatives on future calls. Turning to the quarter, consolidated revenue was $414 million, which is above the high end of our guidance range. And though adjusted EBITDA of $21 million was within our guidance range, it would have been even higher had it not been for a charge to allowance for doubtful accounts, which Bill will cover in more detail. As expected, travel revenue in the fourth quarter was down 12% sequentially, on track with our expectations for both rates and volumes. Looking ahead, travel bill rates continue to stabilize and are trending in line with expectations. As we have called out previously, there remains a gap in expectations around bill rates with clients and pay rates from clinicians on many orders, impacting both our fill rate as well as our margins. As we navigate this dynamic, we will remain competitive in order to preserve our market share, while balancing overall profitability. Turning to our other business lines, Physician Staffing continued its strong performance with reported fourth quarter revenue of 26% year-over-year, quickly approaching an annual run rate of $200 million. Driving this was a combination of higher billable days and an improved mix of higher bill rate specialties. The segment’s contribution to income reflects the ongoing investments we are making in the business that we believe will drive organic growth and margin expansion throughout 2024. Our Education business continued to perform well, up 9% from the prior year and more than 50% from the third quarter following the start of the new school year. Our Homecare business was flat sequentially and year-over-year, though we exited the year on a solid trajectory. As we reported last quarter, we had five Homecare MSP wins and presently have nine programs in implementation. On the backs of these wins, I believe this business will experience strong organic growth in 2024. Now, turning to our outlook for the first quarter, given my earlier comments on the current market backdrop, including recent travel demand trends and industry-wide margin pressure, we anticipate that first quarter revenue will be between $370 million and $380 million, with adjusted EBITDA coming in at $13 million to $18 million. As a reminder, the annual reset in payroll taxes compresses margins at the beginning of the calendar year. I want to stress, as we work through the current market climate, we are taking actions to drive organic growth and margin expansion. In addition to ramping recent vendor-neutral and MSP wins across acute care and pay settings, we will continue to diversify physician staffing into higher margin modalities, as well as seek to capitalize on our growth and education through geographic expansion into even more markets. Additionally, we will remain diligent on the M&A front, with a goal to close on several accretive acquisitions that can further enhance our value proposition and diversify our platform into higher margin offerings. Looking ahead, we will continue to balance investments that serve to further diversify and differentiate Cross Country with necessary cost savings to preserve profitability, such as leveraging our operations in India. In fact, I just came back from India, where we held our 2024 company-wide kickoff. Coupled with the enhanced productivity and efficiency gains we are seeing through technology investments, I remain confident in our ability to drive long-term, sustainable, profitable growth, and we intend to remain focused on increasing shareholder value by leveraging our balance sheet and through the deployment of capital, including additional share repurchases, ongoing technology investments, and potential M&A opportunities. In closing, we are confident about our prospects for 2024. Outside of the broader pressures in travel, we are seeing strong momentum with Intellify, Locums, Education, and our Homecare business. The team continues to execute at a very high level, and none of this is possible without our devoted employees. We were recently named a 2023 winner of Best Company Culture and Best Company for Diversity by Comparably. These recognitions say something about our tapestry of culture that we work so hard to uphold, making Cross Country the employer destination of choice. I want to thank all of our employees and our healthcare professionals for your continued hard work and contributions, as well as our shareholders for believing in the company. With that, let me turn the call over to Bill.